⌕
CRISPR Therapeutics · CRSP · Nasdaq
Tenet 54 · Mixed
Compare
$42.24−0.89%At closeTenet 54 · Mixed
$42.24−0.38 (−0.89%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

CRISPR Therapeutics (CRSP) Stock

CRISPR Therapeutics (CRSP) closed at $42.24 on Nov 13, 2026; its Tenet Score is 54 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

30 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$42.24
Nov 13, 2026
Market cap
$4.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
41.75 – 63.45
low → high
Tenet Score
54/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

CRISPR Therapeutics AG scores 54/100. Mixed. Strongest on financial health and value, quality is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
54/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
71
Quality
28
Health
77
Growth
42

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityFHealthBGrowthDMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.5×
price to book value
P/S
162.8×
price to fiscal 2025 sales
ROE
−26%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
16.21
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 80 US ETFs · top wrappers by weightSee all ETFs holding CRSP →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

Compare CRISPR Therapeutics with

What sector and industry is CRISPR Therapeutics in?

CRISPR Therapeutics is in the Healthcare sector and the Drugs industry.

What is CRISPR Therapeutics' Tenet Score?

CRISPR Therapeutics' Tenet Score is 54 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.